Fmr LLC Hookipa Pharma Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Hookipa Pharma Inc. stock. As of the latest transaction made, Fmr LLC holds 3,404,001 shares of HOOK stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,404,001

Previous 3,358,383 1.36%

Holding current value

$12.8 Million

Previous $2.38 Million 15.77%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.59 - $1.04 $26,914 - $47,442	45,618 Added 1.36%	3,404,001 $2.01 Million
Q3 2023 Nov 13, 2023	SELL	$0.58 - $0.91 $852,055 - $1.34 Million	-1,469,061 Reduced 30.43%	3,358,383 $2.08 Million
Q2 2023 Aug 11, 2023	SELL	$0.71 - $1.97 $48,461 - $134,464	-68,256 Reduced 1.39%	4,827,444 $4.25 Million
Q1 2023 May 11, 2023	BUY	$0.72 - $1.03 $72 - $103	100 Added 0.0%	4,895,700 $3.62 Million
Q4 2022 Feb 13, 2023	SELL	$0.73 - $14.6 $102,232 - $2.04 Million	-140,045 Reduced 2.78%	4,895,600 $3.97 Million
Q3 2022 Nov 10, 2022	SELL	$1.27 - $15.0 $810,978 - $9.58 Million	-638,566 Reduced 11.25%	5,035,645 $6.75 Million
Q2 2022 Aug 12, 2022	SELL	$1.33 - $2.31 $1,940 - $3,370	-1,459 Reduced 0.03%	5,674,211 $9.25 Million
Q1 2022 May 13, 2022	BUY	$1.26 - $2.52 $4.52 Million - $9.04 Million	3,585,470 Added 171.54%	5,675,670 $12.9 Million
Q4 2021 Feb 14, 2022	SELL	$2.33 - $5.94 $324,802 - $828,036	-139,400 Reduced 6.25%	2,090,200 $4.87 Million
Q3 2021 Nov 15, 2021	BUY	$5.89 - $9.35 $1.17 Million - $1.86 Million	199,000 Added 9.8%	2,229,600 $13.1 Million
Q2 2021 Aug 13, 2021	BUY	$9.16 - $19.51 $18.6 Million - $39.6 Million	2,030,600 New	2,030,600 $18.6 Million

Others Institutions Holding HOOK

# of Institutions

Shares Held

23.5M

Call Options Held

98.5K

Put Options Held

46.6K

View Full List

About HOOKIPA Pharma Inc.

Ticker HOOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,654,500
Market Cap $194M
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...

More about HOOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account